据介绍，宜明昂科开发的新一代CTLA-4抗体泰泽苏拜单抗(tazlestobart，IMM27M)通过清除肿瘤微环境 中的Treg细胞而发挥抗肿瘤疗效。目前宜明昂科正积极推进泰泽苏拜单抗的临床开发。泰泽苏拜单抗 (tazlestobart，IMM27M)是宜明昂科公司自主研发的新一代CTLA-4抗体，通过基因工程技术加强了 ADCC活性，可以全面清除肿瘤微环境中的Treg细胞。IMM27M是一种针对Treg细胞的创新药物，其主 要作用机制是通过靶向Treg细胞上的特定分子CTLA-4，调节其功能或数量，从而增强免疫反应。 消息面上，据宜明昂科-B官微消息，近日，玛丽.E.布伦科等三位科学家被授予2025年诺贝尔生理学或 医学奖，以表彰他们在外周免疫耐受机制领域的研究成果。这一创新性研究成果找到了免疫系统的抑制 开关，为全球数亿自身免疫病及癌症患者带来颠覆性疗法。调节性T细胞(Treg细胞)通过Foxp3转录因子 维持免疫耐受，其功能异常与自身免疫病、癌症等密切相关，而细胞毒性T淋巴细胞相关抗原4(CTLA- 4)是Treg细胞执行免疫抑制功能的"关键效应分子"。Treg细胞的发现及其作用机制研究，为开发新一代 ...

Core Viewpoint - The stock of Iminconco-B (01541) has risen over 5% due to increased attention on Treg cell therapy and the active clinical development of Tazlestobart monoclonal antibody [1][2] Group 1: Company Developments - Iminconco-B's stock price increased by 5.22%, reaching 11.47 HKD, with a trading volume of 40.47 million HKD [1] - The company is actively advancing the clinical development of Tazlestobart (IMM27M), a next-generation CTLA-4 antibody [2] Group 2: Scientific Recognition - Three scientists, including Mary E. Blenko, were awarded the 2025 Nobel Prize in Physiology or Medicine for their research on peripheral immune tolerance mechanisms, which has implications for autoimmune diseases and cancer therapies [1] - The discovery of regulatory T cells (Treg cells) and their mechanisms has provided a theoretical foundation for developing new immunomodulatory drugs [1] Group 3: Product Mechanism - Tazlestobart (IMM27M) is designed to eliminate Treg cells in the tumor microenvironment, enhancing anti-tumor efficacy [2] - The drug utilizes genetic engineering to enhance ADCC activity and targets specific molecules on Treg cells, particularly CTLA-4, to modulate their function or quantity [2]

Group 1 - The stock of I-Mab (01541) increased by over 10%, reaching HKD 7.66 with a trading volume of HKD 40.02 million [1] - I-Mab announced the approval of its clinical trial application for Tazlestobart (IMM27M) in combination with Osimertinib for EGFR-mutant locally advanced or metastatic non-squamous non-small cell lung cancer by the National Medical Products Administration (NMPA) [1] - The company received a second payment of USD 5 million from Axion Bio, bringing the total amount received for the collaboration on IMM2510 and IMM27M to USD 20 million [1] Group 2 - Guoyuan International highlighted I-Mab as a research-driven biotechnology company capable of systematically utilizing both innate and adaptive immunity [2] - I-Mab is developing two CD47×CD20 bispecific antibodies/fusion proteins, with IMM0306 being the first to enter clinical trials, showing an overall response rate (ORR) of 90.9% and a complete response (CR) of 27.3% in an Ib trial with 11 patients [2] - Clinical trials for autoimmune diseases are currently in the Ib phase, with the SLE trial enrolling six patients in the second dose group, showing promising response rates, and data is expected to be released mid-year [2]